Rosalind Advisors Inc. Makes New Investment in X4 Pharmaceuticals, Inc. $XFOR

Rosalind Advisors Inc. acquired a new stake in shares of X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 1,544,607 shares of the company’s stock, valued at approximately $5,283,000. X4 Pharmaceuticals comprises approximately 1.9% of Rosalind Advisors Inc.’s holdings, making the stock its 19th biggest position. Rosalind Advisors Inc. owned 13.54% of X4 Pharmaceuticals at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently made changes to their positions in the business. Palumbo Wealth Management LLC bought a new position in X4 Pharmaceuticals in the 3rd quarter valued at about $326,000. Vanguard Group Inc. increased its holdings in X4 Pharmaceuticals by 77.0% during the 3rd quarter. Vanguard Group Inc. now owns 410,485 shares of the company’s stock worth $1,404,000 after purchasing an additional 178,593 shares in the last quarter. Jane Street Group LLC raised its stake in shares of X4 Pharmaceuticals by 112.5% in the second quarter. Jane Street Group LLC now owns 97,344 shares of the company’s stock worth $185,000 after purchasing an additional 51,544 shares during the last quarter. Rhumbline Advisers raised its stake in shares of X4 Pharmaceuticals by 5.4% in the first quarter. Rhumbline Advisers now owns 188,415 shares of the company’s stock worth $44,000 after purchasing an additional 9,690 shares during the last quarter. Finally, Bank of America Corp DE raised its stake in shares of X4 Pharmaceuticals by 20.3% in the fourth quarter. Bank of America Corp DE now owns 133,502 shares of the company’s stock worth $98,000 after purchasing an additional 22,485 shares during the last quarter. Institutional investors and hedge funds own 72.03% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts recently issued reports on XFOR shares. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of X4 Pharmaceuticals in a research report on Monday, December 29th. Guggenheim assumed coverage on X4 Pharmaceuticals in a research report on Monday. They issued a “buy” rating and a $12.00 price target for the company. Stifel Nicolaus set a $10.00 price objective on shares of X4 Pharmaceuticals and gave the stock a “buy” rating in a report on Friday, December 5th. Zacks Research downgraded shares of X4 Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Wednesday, November 26th. Finally, Wall Street Zen lowered shares of X4 Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Sunday, November 30th. Four analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $28.88.

X4 Pharmaceuticals Trading Down 10.4%

NASDAQ XFOR opened at $3.88 on Friday. The business’s fifty day moving average is $3.66 and its 200-day moving average is $3.63. The company has a debt-to-equity ratio of 1.23, a current ratio of 5.65 and a quick ratio of 5.48. The stock has a market capitalization of $339.27 million, a price-to-earnings ratio of -0.38 and a beta of 0.43. X4 Pharmaceuticals, Inc. has a one year low of $1.35 and a one year high of $10.49.

About X4 Pharmaceuticals

X4 Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the development of novel therapies targeting the C-X-C chemokine receptor type 4 (CXCR4) for the treatment of rare immunological diseases and oncology indications. The company’s lead asset, mavorixafor, is an orally administered, selective small-molecule CXCR4 antagonist designed to mobilize white blood cells and enhance immune function, with a primary focus on WHIM syndrome, a rare congenital immunodeficiency.

Beyond its WHIM syndrome program, X4 is advancing mavorixafor in clinical trials for additional hematologic and solid tumor settings—such as Waldenström’s macroglobulinemia and chronic lymphocytic leukemia—where modulation of the CXCR4 pathway may improve patient outcomes.